title: Immunogenicity and protective efficacy of a dual subunit vaccine against respiratory syncytial virus and influenza virus.
abstract: Respiratory syncytial virus (RSV) and influenza virus are the most significant pathogens causing respiratory tract diseases. Composite vaccines are useful in reducing the number of vaccination and confer protection against multiple infectious agents. In this study, we generated fusion of RSV G protein core fragment (amino acid residues 131 to 230) and influenza HA1 globular head domain (amino acid residues 62 to 284) as a dual vaccine candidate. This fusion protein, Gcf-HA1, was bacterially expressed, purified by metal resin affinity chromatography, and refolded in PBS. BALB/c mice were intranasally immunized with Gcf-HA1 in combination with a mucosal adjuvant, cholera toxin (CT). Both serum IgG and mucosal IgA responses specific to Gcf and HA1 were significantly increased in Gcf-HA1/CT-vaccinated mice. To determine the protective efficacy of Gcf-HA1/CT vaccine, immunized mice were challenged with RSV (A2 strain) or influenza virus (A/PR/8/34). Neither detectable viral replication nor pathology was observed in the lungs of the immune mice. These results demonstrate that immunity induced by intranasal Gcf-HA1/CT immunization confers complete protection against both RSV and homologous influenza virus infection, suggesting our Gcf-HA1 vaccine candidate could be further developed as a dual subunit vaccine against RSV and influenza virus.
authors: Division of Life & Pharmaceutical Sciences, Ewha Womans University, Seoul 120-750, Korea.
authors: Min-Hee
authors: MH
authors: Park
authors: Jun
authors: J
authors: Chang
keywords: Dual vaccine; G glycoprotein; Hemagglutinin; Influenza virus; Intranasal immunization; Protective immunity; Respiratory syncytial virus
references: J Virol. 1996 May;70(5):2852-60
references: 8627759
references: PLoS One. 2008 May 21;3(5):e2257
references: 18493310
references: Pediatr Res. 1976 Jan;10(1):75-8
references: 1246465
references: PLoS One. 2012;7(2):e32226
references: 22384186
references: J Virol. 1994 Aug;68(8):5321-5
references: 8035532
references: Immunol Rev. 2011 Jan;239(1):167-77
references: 21198671
references: J Clin Microbiol. 1988 Aug;26(8):1595-7
references: 2459154
references: Vaccine. 2000 Dec 8;19(9-10):1038-46
references: 11137237
references: Cell. 1982 Dec;31(2 Pt 1):417-27
references: 6186384
references: PLoS One. 2009;4(4):e5190
references: 19360100
references: Vaccine. 2011 Aug 5;29(34):5657-65
references: 21704111
references: Vaccine. 1990 Apr;8(2):164-8
references: 2336876
references: Nat Immunol. 2001 Aug;2(8):732-8
references: 11477410
references: J Virol. 1999 Jul;73(7):5637-45
references: 10364313
references: Immune Netw. 2012 Feb;12(1):8-17
references: 22536165
references: J Virol. 2008 Mar;82(5):2350-7
references: 18094185
references: PLoS One. 2011;6(9):e23797
references: 21915262
references: Drugs Aging. 2005;22(7):577-87
references: 16038573